Clinical Trial

Real World Evidence of Tivozanib as First-line Treatment for Metastatic Clear Cell Renal Cell Carcinoma

Study acronym: SOGUG-TIVOREAL
Completed
View on ClinicalTrials.gov →
Summary
The SOGUG-TIVOREAL study is a retrospective observational study with medications. This study is based on the retrospective collection of data from patients who have been treated with Tivozanib as first-line therapy between 03/01/2019 and 08/31/2024 for metastatic renal cell carcinoma (mRCC).
Trial Details
NCT Number NCT07354282
Lead Sponsor Spanish Oncology Genito-Urinary Group
Collaborators: Adknoma Health Research
Conditions Renal Cell Cancer Metastatic
Enrollment 200 participants
Start Date 2025-05-13
Primary Completion 2025-08-07 (estimated)
Study Completion 2025-08-07 (estimated)
Updated on ClinicalTrials.gov 2026-01-21